Urinary metabolomics of bronchopulmonary dysplasia (BPD): preliminary data at birth suggest it is a congenital disease

Fanos, Vassilios; Pintus, Maria Cristina; Lussu, Milena; Atzori, Luigi; Noto, Antonio; Stronati, Mauro; Guimarães, Hercília; Marcialis, Maria Antonietta; Rocha, Gustavo; Moretti, Corrado; Papoff, Paola; Lacerenza, Serafina; Puddu, Selena; Giuffrè, Mario; Serraino, Francesca; Mussap, Michele; Corsello, Giovanni

doi:10.3109/14767058.2014.955966

Cited by 50 publications

(51 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the high taurine urinary level in the group of dead babies may be considered an index of cell necrosis and death due to hypoxia. closely comparable behavior to that found in this study, confirming the key role of this metabolite in predicting clinical outcome (44). The trend over time of lysine is similar to that of lactic acid and taurine.…”

Section: Discussionsupporting

confidence: 72%

Urinary gas chromatography mass spectrometry metabolomics in asphyxiated newborns undergoing hypothermia: from the birth to the first month of life

Noto¹,

Pomero²,

Mussap³

et al. 2016

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

Background: Perinatal asphyxia is a severe clinical condition affecting around four million newborns worldwide.It consists of an impaired gas exchange leading to three biochemical components: hypoxemia, hypercapnia and metabolic acidosis. Methods:The aim of this longitudinal experimental study was to identify the urine metabolome of newborns with perinatal asphyxia and to follow changes in urine metabolic profile over time. Twelve babies with perinatal asphyxia were included in this study; three babies died on the eighth day of life. Total-body cooling for 72 hours was carried out in all the newborns. Urine samples were collected in each baby at birth, after 48 hours during hypothermia, after the end of the therapeutic treatment (72 hours), after 1 week of life, and finally after 1 month of life. Urine metabolome at birth was considered the reference against which to compare metabolic profiles in subsequent samples. Quantitative metabolic profiling in urine samples was measured by gas chromatography mass spectrometry (GC-MS). The statistical approach was conducted by using the multivariate analysis by means of principal component analysis (PCA) and orthogonal partial least square discriminant analysis (OPLS-DA). Pathway analysis was also performed. Results:The most important metabolites depicting each time collection point were identified and compared each other. At birth before starting therapeutic hypothermia (TH), urine metabolic profiles of the three babies died after 7 days of life were closely comparable each other and significantly different from those in survivors. Conclusions:In conclusion, a plethora of data have been extracted by comparing the urine metabolome at birth with those observed at each time point collection. The modifications over time in metabolites composition and concentration, mainly originated from the depletion of cellular energy and homeostasis, seems to constitute a fingerprint of perinatal asphyxia.

show abstract

Section: Discussionsupporting

confidence: 72%

Urinary gas chromatography mass spectrometry metabolomics in asphyxiated newborns undergoing hypothermia: from the birth to the first month of life

Noto¹,

Pomero²,

Mussap³

et al. 2016

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…14−16 The noninvasive collection of newborn urine and subsequent ease to address large cohorts, compared to newborn blood, makes it a particularly interesting biofluid in the present context. This has indeed been recognized in reports on the newborn urinary impact of prematurity, 17−20 IUGR, 21−23 large for gestational age (LGA), 22,23 GDM, 3 asphyxia, 11,24,25 respiratory distress syndrome (RDS), 24 meconium aspiration syndrome (MAS), 24 bronchopulmonary dysplasia, 26 IEM, 27 neonatal sepsis, 28 postnatal bacterial, 19 cytomegalovirus, 29 and fungal 30 infections. Most of these studies have considered relatively small cohorts (up to ca.…”

Section: ■ Introductionmentioning

confidence: 99%

Newborn Urinary Metabolic Signatures of Prematurity and Other Disorders: A Case Control Study

et al. 2015

View full text Add to dashboard Cite

This work assesses the urinary metabolite signature of prematurity in newborns by nuclear magnetic resonance (NMR) spectroscopy, while establishing the role of possible confounders and signature specificity, through comparison to other disorders. Gender and delivery mode are shown to impact importantly on newborn urine composition, their analysis pointing out at specific metabolite variations requiring consideration in unmatched subject groups. Premature newborns are, however, characterized by a stronger signature of varying metabolites, suggestive of disturbances in nucleotide metabolism, lung surfactants biosynthesis and renal function, along with enhancement of tricarboxylic acid (TCA) cycle activity, fatty acids oxidation, and oxidative stress. Comparison with other abnormal conditions (respiratory depression episode, large for gestational age, malformations, jaundice and premature rupture of membranes) reveals that such signature seems to be largely specific of preterm newborns, showing that NMR metabolomics can retrieve particular disorder effects, as well as general stress effects. These results provide valuable novel information on the metabolic impact of prematurity, contributing to the better understanding of its effects on the newborn's state of health.

show abstract

“…Comparing the urinary metabolic profiles at birth of preterm neonates, Fanos et al found five discriminant metabolites: lactate, taurine, trimethylamine-N-oxide (TMAO), myo-inositol (which increased in BPD patients), and gluconate (which was decreased) [14]. The increase in urinary lactate in the BPD group may represent a process of anaerobic respiration.…”

Section: Respiratory Distress Syndrome and Bronchopulmonary Dysplasiamentioning

confidence: 99%

Metabolomics in Neonatology

Hanna¹,

Brophy²

2016

Metabolomics - Fundamentals and Applications

View full text Add to dashboard Cite

Throughout recent decades, the incidence of preterm birth has risen worldwide, and although the majority of preterm neonates now survive infancy, many suffer from debilitating morbidities in the short term and/or increased disease risks in the long term. Traditional diagnostic biomarkers suffer from considerable confounders, limiting their use in the early identification of diseases. There is a need to develop novel biomarkers that can identify, in real time, the evolution of organ dysfunction in an early diagnostic, monitoring, and prognostic fashion. Use of "omics," particularly metabolomics, may provide valuable information regarding functional pathways underlying different pathologies and prediction of clinical outcomes. The emerging knowledge generated by the application of metabolomics in neonatology provides new insights that can help to identify markers of early diagnosis, disease progression, response to treatment, and new therapeutic targets. In this chapter, we review the current knowledge of different metabolomics technologies in neonatal-perinatal medicine, including biomarker discovery, defining as yet unrecognized biologic therapeutic targets, and linking of metabolomics to relevant standard indices and long-term outcomes.

show abstract

Urinary metabolomics of bronchopulmonary dysplasia (BPD): preliminary data at birth suggest it is a congenital disease

Cited by 50 publications

References 41 publications

Urinary gas chromatography mass spectrometry metabolomics in asphyxiated newborns undergoing hypothermia: from the birth to the first month of life

Urinary gas chromatography mass spectrometry metabolomics in asphyxiated newborns undergoing hypothermia: from the birth to the first month of life

Newborn Urinary Metabolic Signatures of Prematurity and Other Disorders: A Case Control Study

Metabolomics in Neonatology

Contact Info

Product

Resources

About